Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

IDrugs

Volumn 11, Issue 12, 2008, Pages 906-917

  Gallwitz, B ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; ALUMINUM MAGNESIUM HYDROXIDE; DIGOXIN; DILTIAZEM; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUTOGLIPTIN; EXENDIN 4; FAMOTIDINE; GLIBENCLAMIDE; HEMOGLOBIN A1C; KETOCONAZOLE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; OMEPRAZOLE; ONGLYZA; PF 734200; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SIMETHICONE; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIDE EFFECT;

ADAMANTANE; ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57349125875     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. 482284 Synthesis of novel potent DPP-IV inhibitors with enhanced chemical stability: Interplay between the alkyl fragment of the N-terminal amino acid moiety and the cyclopropyl group of α-aminoacyl- (L)-(cis)-4,5-methanoprolinenitrile-based inhibitors. Magnin D, Robl J, Sulsky RB, Augieri DJ, Huang Y, Taunk P, Betebenner DA, Simpkins LM, Robertson JG, Khanna A, Abboa-Offei B et al ACS 2003 225 MEDI 189
2. 554377 Design, synthesis, and pharmacology of BMS-477118: A long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type II diabetes. Hamann LG, Augeri DJ, Betebenner DA, Robl J, Magnin D, Khann A, Robertson JG, Simpkins LM, Taunk P, Sitkoff D, Weigelt C et al ACS 2004 228 MEDI 207
3. 556348 American Chemical Society - 228th National Meeting (Part VII) - OVERNIGHT REPORT, Philadelphia, PA, USA. Ognjenovic M IDDB MEETING REPORT 2004 August 22-26
4. 572056 Bristol-Myers Squibb R and D review, November 17, 2004. Bristol-Myers Squibb Co COMPANY PRESENTATION 2004 November 17
5. 580792 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes. Zander M, Madsbad S, Madsen JL, Holst JJ Lancet 2002 359 9309 824-830
6. 606500 Newly approved first-in-class treatment for type 2 diabetes is now available. Eli Lilly & Co/Amylin Pharmaceuticals Inc PRESS RELEASE 2005 June 09
7. 676851 Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Kim YB, Kopcho LM, Kirby MS, Hamann LG, Weigelt CA, Metzler WJ, Marcinkeviciene J ARCH BIOCHEM BIOPHYS 2006 445 1 9-18
8. 676852 Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Hamann LG et al J MED CHEM 2005 48 15 5025-5037
9. 753448 Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. announce exclusive licensing agreement for diabetes compound saxagliptin in Japan. Bristol-Myers Squibb Co PRESS RELEASE 2006 December 27
10. 756003 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill M C, Zinman B, Viberti G N ENGL J MED 2006 355 23 2427-2443
11. 756936 Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds. Bristol-Myers Squibb Co PRESS RELEASE 2007 January 11
12. 757301 AstraZeneca and Bristol-Myers Squibb announce worldwide collaboration to develop and commercialise diabetes compounds. AstraZeneca plc PRESS RELEASE 2007 January 11
13. 760659 The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker DJ, Nauck MA LANCET 2006 368 9548 1696-1705
14. 760667 The incretin concept today. Creutzfeldt W DIABETOLOGIA 1979 16 2 75-85 •• This is the first publication describing the physiology of the entero-insular axis.
15. 808165 Data demonstrated saxagliptin added to metformin improved glycemic control in subjects with type 2 diabetes compared to metformin alone. AstraZeneca plc; Bristol-Myers Squibb Co PRESS RELEASE 2007 June 25
16. 808237 Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects. Boulton DW, Geraldes M ANN MEET AM DIABETES ASSOC 2007 67 June 22 Abs 0606-P • This paper provides the first published phase I clinical trial data relating to saxagliptin.
17. 810540 Saxagliptin added to metformin improves glycemic control in patients with type 2 diabetes. Defronzo RA, Hissa M, Blauwet MB, Chen RS ANN MEET AM DIABETES ASSOC 2007 67 June 25 Abs 0285-OR • This is the first report of a phase III clinical trial of saxagliptin as an add-on therapy to metformin.
18. 819085 NCT00121641: Saxagliptin treatment in subjects with type 2 diabetes who are not controlled with diet and exercise. Bristol-Myers Squibb Co CLINICALTRIALS.GOV 2007 August 01
19. 819099 NCT00295633: A study assessing saxagliptin treatment in type 2 diabetic subjects who are not controlled with TZD therapy alone. Bristol-Myers Squibb Co CLINICALTRIALS.GOV 2007 August 01
20. 848551 New safety issues for Galvus delay European launch. Novartis AG PRESS RELEASE 2007 November 06
21. 861815 Galvus, a new oral treatment for type 2 diabetes, receives positive opinion following changes to European prescribing information. Novartis AG PRESS RELEASE 2007 December 17
22. 872709 Summary of financial statements (consolidated) first three quarters results for the fiscal year ending March 31, 2008. Takeda Pharmaceutical Co Ltd PRESS RELEASE 2008 January 31
23. 873599 NCT00601250: Efficacy and safety of BI1356 vs placebo added to metformin background therapy in patients with type 2 diabetes. Boehringer Ingelheim Pharmaceuticals CLINICALTRIALS.GOV 2008
24. 881116 NCT00622284: Efficacy and safety of BI 1356 in combiation with metformin in patients with type 2 diabetes. Boehringer Ingelheim Pharmaceuticals CLINICALTRIALS.GOV 2008
25. 883473 NCT00614939: Treatment effect of saxagliptin compared with placebo in patients with type 2 diabetes and renal impairment. AstraZeneca plc CLINICALTRIALS.GOV 2008 March 5
26. 888877 NCT00374907: A study assessing saxagliptin treatment in subjects with type 2 diabetes who are not controlled with diet and exercise. Bristol-Myers Squibb Co CLINICALTRIALS.GOV 2006 September 07
27. 888918 No pharmacokinetic interaction between saxagliptin and digoxin in healthy subjects. Boulton DW, Li L, Patel CG, Komoroski BJ, Whigan D, Frevert EU, Kornhauser DM CLIN PHARMACOL THER 2008 83 Suppl 1 S93
28. 888943 Magnesium and aluminum hydroxides plus simethicone, famotidine or omeprazole do not meaningfully affect the pharmacokinetics of saxagliptin in healthy subjects. Boulton DW, Adams D, Li L, Patel CG, Komoroski BJ, Whigan D, Frevert EU, Goyal A, Kornhauser DM CLIN PHARMACOL THER 2008 83 Suppl 1 S92-S93
29. 891499 Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: A review of recent clinical trials. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP CURR MED RES OPIN 2008 24 2 489-496
30. 903376 Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Rosenstock J, Sankoh S, List JF DIABETES OBESITY METAB 2008 10 5 376-386 • The first published full paper describing a phase II clinical trial with saxagliptin in drug-naive type 2 diabetic patients.
31. 903377 Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation. Metzler WJ, Yanchunas J, Weigelt C, Kish K, Klei HE, Xie D, Zhang Y, Corbett M, Tamura JK, He B, Marcinkeviciene J et al PROTEIN SCI 2008 17 2 240-250
32. 903379 Carbon-14 labeling of saxagliptin (BMS-477118). Cao, K, Bonacorsi Jr SJ, Balasubramanian B, Godfrey Jr JD, Fox R, Christopher LJ, Su H, Iyer R J LABELLED COMPD RADIOPHARM 2007 50 13 1224-1229
33. 903381 Saxagliptin improves glycaemic control as monotherapy in type 2 diabetes. List J, Rosenstock J, Sankoh S, Chen R DIABETOLOGIA 2007 50 Suppl 1 S367
34. 903382 Effect of ketoconazole on the pharmacokinetics of saxagliptin in healthy subjects. Boulton DW, Brenner E, Royzman K, Li L J CLIN PHARMACOL 2007 47 9 1203
35. 903383 Effect of diltiazem on the pharmacokinetics of saxagliptin in healthy subjects. Girgis S, Patel CG, Li L, Gooding L, Frevert U, Whigan D, Boulton DW J CLIN PHARMACOL 2007 47 9 1199
36. 903385 Effect of simvastatin on the pharmacokinetics of saxagliptin in healthy subjects. Anon J CLIN PHARMACOL 2007 47 9 Abs 28
37. 915053 Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects. Patel C, Castaneda L, Frevert U, Li L, Kornhauser DM, Boulton DW ANN MEET AM DIABETES ASSOC 2008 68 June 08 Abs 537-P
38. 920208 NCT00690638: Safety and efficacy study of dutogliptin/PHX1149T to treat type 2 diabetes mellitus. Phenomix Corp CLINICALTRIALS.GOV 2008
39. 921510 Pharma Japan - Business: Abilify's sales up 24% to US$454 mil in 1st quarter: MBS. PHARMA JPN 2008 2093 June 09 12
40. 927366 Bristol-Myers Squibb and AstraZeneca submit new drug application in the United States and marketing authorization application in Europe for ONGLYZA (saxagliptin) for the treatment of type 2 diabetes. Bristol-Myers Squibb Co PRESS RELEASE 2008 July 23
41. 931232 Implications of the prolonged dissociation rate of saxagliptin, a highly potent and selective DPP4 inhibitor, on plasma DPP measurements. Wang AY, Dorso C, Kopcho L, Marcinkeviciene J, Kirby MS DIABETES 2008 57 Suppl 1 A576-A577
42. 931233 The effects of age and gender on the single-dose pharmacokinetics and safety of saxagliptin in healthy subjects. Boulton DW, Goyal A, Li L, Korn-Hauser DM, Frevert U DIABETES 2008 57 Suppl 1 A164
43. 931238 Once-daily saxagliptin monotherapy improves glycemic control in drug-naive patients with type 2 diabetes. Rosenstock J, Aguilar-Salinas CA, Klein E, List J, Blauwet MB, Chen R DIABETES 2008 57 Suppl 1 A154
44. 931353 Diabetes and obesity: The twin epidemics. Smyth S, Heron A NAT MED 2006 12 1 75-80
45. 931356 Islet β cell failure in type 2 diabetes. Prentki M, Nolan CJ J CLIN INVEST 2006 116 7 1802-1812
46. 931358 Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Gallwitz B Minerva ENDOCRINOL 2006 31 2 133-147
47. 931364 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W J CLIN INVEST 1993 91 1 301-307 • Describes an important clinical trial demonstrating the reduced incretin effect in patients with type 2 diabetes resulting from an isolated reduction in insulinotropic activity of GIP.
48. 931369 The biology of incretin hormones. Drucker DJ CELL METAB 2006 3 3 153-165
49. 931370 Dipeptidyl-peptidase IV (CD26) - Role in the inactivation of regulatory peptides. Mentlein R REGUL PEPT 1999 85 1 9-24 • Provides an important review of DPP-IV action and DPP-IV substrates.
50. 931378 Update: Vildagliptin for the treatment of type 2 diabetes. Garber AJ, Sharma MD EXPERT OPIN INVEST DRUGS 2008 17 1 105-113
51. 947678 Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. Saydah SH, Fradkin J, Cowie CC J AM MED ASSOC 2004 291 3 335-342
52. 947681 Sitagliptin in clinical practice: A new approach in the treatment of type 2 diabetes. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS EXPERT OPIN PHARMACOTHER 2008 9 10 1705-1720
53. 949452 US-20060035954: Ammonolysis process for the preparation of intermediates for DPP-IV inhibitors. Sharma PN, Galvin GM, Boettger SD, Racha S, Zhu J, Melton J, Mudryk BM US PATENT 2006 February 06
54. 950369 Status of development/marketing of DPP-4 inhibitors. PHARMA JAPAN 2008 2107 15
55. 950382 NCT00770302: Assess pharmacokinetics, safety and tolerability in healthy Chinese volunteers after oral doses of saxagliptin. Bristol-Myers Squibb Co CLINICALTRIALS.GOV 2008
56. 951554 NCT00121667: Study assessing saxagliptin treatment in type 2 diabetic subjects who are not controlled with metformin alone. Bristol-Myers Squibb Co CLINICALTRIALS.GOV 2008
57. 951635 NCT00327015: A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise. Bristol-Myers Squibb Co CLINICALTRIALS.GOV 2008
58. 951660 NCT00313313: A study of saxagliptin in subjects with type 2 diabetes who have inadequate blood sugar control with sulfonylureas. Bristol-Myers Squibb Co CLINICALTRIALS.GOV 2008
59. 951667 NCT00316082: Study of BMS-477118 as monotherapy with titration in subjects with type 2 diabetes who are not controlled with diet and exercise. Bristol-Myers Squibb Co CLINICALTRIALS.GOV 2008
60. 951677 NCT00575588: 52-Week add-on to metformin comparison of saxagliptin and sulfonylurea. Bristol-Myers Squibb Co/AstraZeneca plc CLINICALTRIALS.GOV 2008
61. 951681 NCT00666458: 18-Week add-on to metformin comparison of saxagliptin and sitagliptin. Bristol-Myers Squibb Co/AstraZeneca plc CLINICALTRIALS.GOV 2008
62. 951683 NCT00683657: Safety and efficacy study of subjects that are taking saxagliptin added onto metformin XR compared to subjects taking metformin XR alone. Bristol-Myers Squibb Co CLINICALTRIALS.GOV 2008
63. 951688 NCT00698932: Evaluate efficacy and safety of saxagliptin in adult patients with type 2 diabetes inadequate glycemic control. Bristol-Myers Squibb Co/AstraZeneca plc CLINICALTRIALS.GOV 2008
64. 951691 NCT00661362: Evaluate efficacy and safety of saxagliptin in combination with metformin in adult patients with type 2 diabetes. Bristol-Myers Squibb Co/AstraZeneca plc CLINICALTRIALS.GOV 2008
65. 951696 NCT00757588: Safety and efficacy study of saxagliptin added to insulin alone or to insulin taken with metformin. Bristol-Myers Squibb Co/AstraZeneca plc CLINICALTRIALS.GOV 2008
66. 952254 WO-2005106011: Process for preparing dipeptidyl IV inhibitors and intermediates therefor. Politino M, Cadin MM, Skonezny PM, Chen JG WORLD PATENT 2005 November 10
67. 952259 US-07205432: Process for the preparation of adamantane derivatives. Berner M, Partanen R, Salakka A, Somersalo P US PATENT 2006 November 30
68. 956151 A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide and metformin in recently diagnosed type 2 diabetes. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Freed MI et al DIABETES CARE 2002 25 10 1737-1743
69. 956152 The United Kingdom Prospective Diabetes Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Bretzel RG, Voigt K, Schatz H EXP CLIN ENDOCRINOL DIABETES 1998 106 5 369-372
70. 956471 Saxagliptin added to a thiazolidinedione improves glycemic control in patients with inadequately controlled type 2 diabetes. Hollander P, Allen E, Li J, Chen R EUR ASSOC STUDY DIABETES ANN MEET 2008 September 7-11 P859
71. 956654 Saxagliptin added to a submaximal-dose sulfonylurea is safe and more efficacious than up-titrating a sulfonylurea in patients with type 2 diabetes. Ravichandran S, Chacra AR, Tan GH, Apanovitch AM, Chen R EUR ASSOC STUDY DIABETES ANN MEET 2008 September 7-11 P858
72. 956683 Initial combination therapy with saxagliptin and metformin improves glycemic control compared with either monotherapy alone in drug-naive patients with type 2 diabetes (CV181-039). Chen R, Pfützner A, Jadzinsky M, Paz-Pacheco E, Xu Z, Allen E EUR ASSOC STUDY DIABETES ANN MEET 2008 September 7-11
73. 957594 No meaningful pharmacokinetic drug-drug interaction between saxagliptin and pioglitazone in healthy subjects. Patel CG, Wolf RA, Komoroski B, Li L, Boulton DW AM COLLEGE CLIN PHARM ANN MEET 2006 October 26-29
74. 957596 No meaningful pharmacokinetic drug-drug interaction between saxagliptin and glyburide in healthy subjects. Patel CG, Wolf RA, Komoroski B, Li L, Boulton DW AM COLLEGE OF CLINICAL PHARMACY ANNUAL MEETING 2006 October 26-29
75. 957597 No meaningful pharmacokinetic drug-drug interaction between saxagliptin and metformin in healthy subjects. Patel CG, Komoroski B, Brenner E, Li L, Boulton DW AM COLLEGE OF CLINICAL PHARMACY ANNUAL MEETING 2006 October 26-29